Skip to main content
group of doctors wearing lab coat and watching at white board


Our focus

Electronic implantable technologies that help patients manage debilitating chronic pain and neurological conditions such as movement disorders.

Matt's story

There is no one-size-fits-all treatment for pain and neurological diseases, such as Parkinson’s disease. Each patient’s needs are unique and personal, which is why physicians need customizable treatment solutions. At Boston Scientific, we’re dedicated to working closely with both physicians and patients to develop meaningful, industry-leading solutions that can improve the quality of life for millions worldwide.

Delivering meaningful innovation

Advancing deep brain stimulation.

 Because Parkinson’s disease is a progressive, neurodegenerative disorder, it’s critical to provide therapy that is designed to adapt with the patient’s evolving needs. The Vercise Genus™ Deep Brain Stimulation (DBS) System with the broadest rechargeable and non-rechargeable battery portfolio in the market, is MRI conditional.1 With our proprietary Multiple Independent Current Control (MICC) and the Vercise Cartesia™ Directional Leads, physicians can offer unmatched precision, flexibility and control. These unique therapy options combined with advanced image guided programming features are designed to make it easier than ever to manage patients' symptoms and help reduce unwanted side effects and adapt for continued symptom relief as the disease progresses.

Personalizing pain therapy.

 Each patient experiences pain differently, and pain can change over time. That’s why the WaveWriter Alpha™ Spinal Cord Stimulator (SCS) Systems are designed to provide personalized, long-lasting pain relief. The portfolio of SCS devices is full-body MRI conditional2, offering proprietary Fast Acting Sub-perception Therapy (FAST™) engineered to provide profound paresthesia-free pain relief to patients in minutes. With the ability to provide multiple therapies in one device, patients and their physicians are given the options to find the therapy that works best for them.

Setting the standard.

The VertiflexTM Procedure (SuperionTM Indirect Decompression System) is a clinically proven, minimally invasive solution designed to deliver long-term relief for the pain associated with moderate lumbar spinal stenosis (LSS). In a clinical study, many patients reduced the use of opioids after the Vertiflex Procedure.3,4

Leading radiofrequency ablation.

We offer radiofrequency ablation (RFA) systems used by physicians to treat patients with chronic pain. RFA is a versatile outpatient procedure that is often used prior to SCS in the treatment continuum for chronic pain and has more than 50-year track record of providing relief for patients.

check icon

85 percent drop in opioid use (among Vertiflex procedure study completers).⁴,⁵

check icon

150,000 Parkinson's disease patients have undergone DBS and regained control and quality of life.⁶

check icon

Patients with tremor experienced an average of 70% reduction of symptoms, depending on type and location.⁷

Conditions we treat

  • Chronic Pain
  • Lumbar Spinal Stenosis
  • Parkinson’s Disease


of people worldwide have chronic pain.9


People with chronic pain are three times more likely to develop symptoms of anxiety. 10


individuals live with Parkinson's disease worldwide.11

Solutions we offer

  • Rechargeable and Non-rechargeable Spinal Cord Stimulator (SCS) Systems
  • Indirect Decompression Systems
  • Radiofrequency Ablation Systems
  • Rechargeable and Non-rechargeable Deep Brain Stimulation Systems

Product spotlights


Results from clinical studies are not predictive of results in other studies. Results in other studies may vary.

  1. The Vercise Genus™ DBS System provides MRI access to full-body 1.5T scans when used under certain conditions as defined in the supplemental manual ImageReady™ MRI Guidelines for Boston Scientific DBS Systems.
  2. The WaveWriter Alpha™ and WaveWriter Alpha™ Prime Spinal Cord Stimulator Systems provide safe access to full-body 1.5T MRI scans when used with specific components and exposed to the MRI environment under the defined conditions in the ImageReady™ MRI Full Body Guidelines for WaveWriter Alpha™ and WaveWriter Alpha™ Prime Spinal Cord Stimulator Systems
  3. North, James, MD. WHISPER: A Multicenter, Prospective Randomized Controlled Trial Evaluating Subperception SCS at ≤ 1.2 kHz. Presentation at North American Neuromodulation Society (NANS), Las Vegas, NV, January 11-14, 2018. (N=70)
  4. Nunley, et al. Journal of Pain Research. 2018:11 2943–2948.
  5. Decrease in the proportion of patients using opioids compared to baseline at five year interval.
  6. International Neuromodulation Society.
  7. Farris SM, Giroux, ML. (2013). DBS: A Patient Guide to Deep Brain Stimulation. 1st ed. CreateSpace Independent Publishing Platform; 2013.
  8. Cohen, P., Steven, Hooten, M., William, Vase, Lene (2021). Chronic pain: an update on burden, best practices, and new advances. Lancet Journal.
  9. Harvard Health Publishing, Depression and Pain, March 21, 2017;

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.

All trademarks are the property of their respective owners